These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36813655)

  • 41. GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia.
    Hu X; Dallinga-Thie GM; Hovingh GK; Chang SY; Sandoval NP; Dang TLP; Fukamachi I; Miyashita K; Nakajima K; Murakami M; Fong LG; Ploug M; Young SG; Beigneux AP
    J Clin Lipidol; 2017; 11(4):964-971. PubMed ID: 28666713
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genotype-phenotype relationships in patients with type I hyperlipoproteinemia.
    Chokshi N; Blumenschein SD; Ahmad Z; Garg A
    J Clin Lipidol; 2014; 8(3):287-95. PubMed ID: 24793350
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pathogenic classification of LPL gene variants reported to be associated with LPL deficiency.
    Rodrigues R; Artieda M; Tejedor D; Martínez A; Konstantinova P; Petry H; Meyer C; Corzo D; Sundgreen C; Klor HU; Gouni-Berthold I; Westphal S; Steinhagen-Thiessen E; Julius U; Winkler K; Stroes E; Vogt A; Hardt P; Prophet H; Otte B; Nordestgaard BG; Deeb SS; Brunzell JD
    J Clin Lipidol; 2016; 10(2):394-409. PubMed ID: 27055971
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Familial chylomicronemia syndrome: pediatric experience in Argentina].
    Araujo MB; Eiberman G; Etcheverry N; Pacheco G
    Arch Argent Pediatr; 2022 Jun; 120(3):e123-e127. PubMed ID: 35533124
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alterations in plasma triglycerides lipolysis in patients with history of multifactorial chylomicronemia.
    Marmontel O; Di Filippo M; Marcais C; Nony S; Dumoux M; Serveaux-Dancer M; Caussy C; Charrière S; Moulin P
    Atherosclerosis; 2017 Oct; 265():22-28. PubMed ID: 28829998
    [TBL] [Abstract][Full Text] [Related]  

  • 46. GPIHBP1 and Plasma Triglyceride Metabolism.
    Fong LG; Young SG; Beigneux AP; Bensadoun A; Oberer M; Jiang H; Ploug M
    Trends Endocrinol Metab; 2016 Jul; 27(7):455-469. PubMed ID: 27185325
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.
    Blom DJ; O'Dea L; Digenio A; Alexander VJ; Karwatowska-Prokopczuk E; Williams KR; Hemphill L; Muñiz-Grijalvo O; Santos RD; Baum S; Witztum JL
    J Clin Lipidol; 2018; 12(5):1234-1243.e5. PubMed ID: 30318066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
    Chaudhry R; Viljoen A; Wierzbicki AS
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel GPIHBP1 mutation related to familial chylomicronemia syndrome: A series of cases.
    Lima JG; Helena C Nobrega L; Moura Bandeira FT; Pires Sousa AG; Medeiros de Araujo Macedo TB; Cavalcante Nogueira AC; Fernandes de Oliveira Filho A; Alves RJ; Costa Gurgel Castelo MH; Silva Coelho FM; Maia RE; Lima DN; Timoteo ARS; de Melo Campos JTA
    Atherosclerosis; 2021 Apr; 322():31-38. PubMed ID: 33706081
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial.
    Rosenson RS; Gaudet D; Ballantyne CM; Baum SJ; Bergeron J; Kershaw EE; Moriarty PM; Rubba P; Whitcomb DC; Banerjee P; Gewitz A; Gonzaga-Jauregui C; McGinniss J; Ponda MP; Pordy R; Zhao J; Rader DJ
    Nat Med; 2023 Mar; 29(3):729-737. PubMed ID: 36879129
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Non-Alcoholic Fatty Liver in Patients with Chylomicronemia.
    Maltais M; Brisson D; Gaudet D
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33572376
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification and characterization of two novel mutations in the LPL gene causing type I hyperlipoproteinemia.
    Pingitore P; Lepore SM; Pirazzi C; Mancina RM; Motta BM; Valenti L; Berge KE; Retterstøl K; Leren TP; Wiklund O; Romeo S
    J Clin Lipidol; 2016; 10(4):816-823. PubMed ID: 27578112
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Familial chylomicronemia syndrome: A rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis.
    Chyzhyk V; Brown AS
    Trends Cardiovasc Med; 2020 Feb; 30(2):80-85. PubMed ID: 31003756
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structure of the lipoprotein lipase-GPIHBP1 complex that mediates plasma triglyceride hydrolysis.
    Birrane G; Beigneux AP; Dwyer B; Strack-Logue B; Kristensen KK; Francone OL; Fong LG; Mertens HDT; Pan CQ; Ploug M; Young SG; Meiyappan M
    Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1723-1732. PubMed ID: 30559189
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chylomicronemia: Differences between familial chylomicronemia syndrome and multifactorial chylomicronemia.
    Paquette M; Bernard S; Hegele RA; Baass A
    Atherosclerosis; 2019 Apr; 283():137-142. PubMed ID: 30655019
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Homozygosity for two point mutations in the lipoprotein lipase (LPL) gene in a patient with familial LPL deficiency: LPL(Asp9-->Asn, Tyr262-->His).
    Rouis M; Lohse P; Dugi KA; Lohse P; Beg OU; Ronan R; Talley GD; Brunzell JD; Santamarina-Fojo S
    J Lipid Res; 1996 Mar; 37(3):651-61. PubMed ID: 8728326
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia.
    Beigneux AP; Miyashita K; Ploug M; Blom DJ; Ai M; Linton MF; Khovidhunkit W; Dufour R; Garg A; McMahon MA; Pullinger CR; Sandoval NP; Hu X; Allan CM; Larsson M; Machida T; Murakami M; Reue K; Tontonoz P; Goldberg IJ; Moulin P; Charrière S; Fong LG; Nakajima K; Young SG
    N Engl J Med; 2017 Apr; 376(17):1647-1658. PubMed ID: 28402248
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Compound heterozygosity for a new (S259G) and a previously described (G188E) mutation in lipoprotein lipase (LpL) as a cause of chylomicronemia. Mutations in brief no. 183. Online.
    Evans D; Wendt D; Ahle S; Guerra A; Beisiegel U
    Hum Mutat; 1998; 12(3):217. PubMed ID: 10660334
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment.
    Chait A; Eckel RH
    Ann Intern Med; 2019 May; 170(9):626-634. PubMed ID: 31035285
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Familial chylomicronemia syndrome and response to medium-chain triglyceride therapy in an infant with novel mutations in GPIHBP1.
    Ahmad Z; Wilson DP
    J Clin Lipidol; 2014; 8(6):635-639. PubMed ID: 25499947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.